Vascular Pathways of Testosterone: Clinical Implications

1.

Kaushik, M., Sontineni, S. P., & Hunter, C. (2010). Cardiovascular disease and androgens: A review. International Journal of Cardiology, 142(1), 8–14. https://doi.org/10.1016/j.ijcard.2009.10.033.CrossRefPubMed

2.

Michels, G., Er, F., Eicks, M., Herzig, S., & Hoppe, U. C. (2006). Long-term and immediate effect of testosterone on single T-type calcium channel in neonatal rat cardiomyocytes. Endocrinology, 147(11), 5160–5169. https://doi.org/10.1210/en.2006-0186.CrossRefPubMed

3.

Elagizi, A., Kohler, T. S., & Lavie, C. J. (2018). Testosterone and cardiovascular health. Mayo Clinic Proceedings, 93(1), 83–100. https://doi.org/10.1016/j.mayocp.2017.11.006.CrossRefPubMed

4.

Yeap, B. B., Page, S. T., & Grossmann, M. (2018). Testosterone treatment in older men: Clinical implications and unresolved questions from the testosterone trials. The Lancet Diabetes and Endocrinology, 6(8), 659–672. https://doi.org/10.1016/S2213-8587(17)30416-3.CrossRefPubMed

5.

Ruehlmann, D. O., & Mann, G. E. (2000). Rapid non-genomic vasodilator actions of oestrogens and sex steroids. Current Medicinal Chemistry, 7(5), 533–541. https://doi.org/10.2174/0929867003375038.CrossRefPubMed

6.

Longcope, C., Kato, T., & Horton, R. (1969). Conversion of blood androgens to estrogens in normal adult men and women. The Journal of Clinical Investigation, 48(12), 2191–2201. https://doi.org/10.1172/JCI106185.CrossRefPubMedPubMedCentral

7.

Rainey, W. E., & Nakamura, Y. (2008). Regulation of the adrenal androgen biosynthesis. The Journal of Steroid Biochemistry and Molecular Biology, 108(3–5), 281–286. https://doi.org/10.1016/j.jsbmb.2007.09.015.CrossRefPubMed

8.

Hakim, C., Padmanabhan, V., & Vyas, A. K. (2017). Gestational hyperandrogenism in developmental programming. Endocrinology, 158(2), 199–212. https://doi.org/10.1210/en.2016-1801.CrossRefPubMed

9.

Yildiz, O., & Seyrek, M. (2007). Vasodilating mechanisms of testosterone. Experimental and Clinical Endocrinology & Diabetes, 115(1), 1–6. https://doi.org/10.1055/s-2007-949657.CrossRef

10.

Lucas-Herald, A. K., Alves-Lopes, R., Montezano, A. C., Ahmed, S. F., & Touyz, R. M. (2017). Genomic and non-genomic effects of androgens in the cardiovascular system: Clinical implications. Clinical Science (London, England), 131(13), 1405–1418. https://doi.org/10.1042/CS20170090.CrossRef

11.

Bowles, D. K., Maddali, K. K., Ganjam, V. K., Rubin, L. J., Tharp, D. L., Turk, J. R., et al. (2004). Endogenous testosterone increases L-type Ca²⁺ channel expression in porcine coronary smooth muscle. American Journal of Physiology. Heart and Circulatory Physiology, 287(5), H2091–H2098. https://doi.org/10.1152/ajpheart.00258.2004.CrossRefPubMed

12.

Zhou, P., Fu, L., Pan, Z., Ma, D., Zhang, Y., Qu, F., et al. (2008). Testosterone deprivation by castration impairs expression of voltage-dependent potassium channels in rat aorta. European Journal of Pharmacology, 593(1–3), 87–91. https://doi.org/10.1016/j.ejphar.2008.07.014.CrossRefPubMed

13.

Oka, M., Karoor, V., Homma, N., Nagaoka, T., Sakao, E., Golembeski, S. M., et al. (2007). Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. Cardiovascular Research, 74(3), 377–387. https://doi.org/10.1016/j.cardiores.2007.01.021.CrossRefPubMedPubMedCentral

14.

Er, F., Gassanov, N., Brandt, M. C., Madershahian, N., & Hoppe, U. C. (2009). Impact of dihydrotestosterone on L-type calcium channels in human ventricular cardiomyocytes. Endocrine Research, 34(3), 59–67. https://doi.org/10.1080/07435800903136953.CrossRefPubMed

15.

Saldanha, P. A., Cairrao, E., Maia, C. J., & Verde, I. (2013). Long- and short-term effects of androgens in human umbilical artery smooth muscle. Clinical and Experimental Pharmacology and Physiology, 40, 181–189. https://doi.org/10.1111/1440-1681.12047.CrossRefPubMed

16.

Yu, J., Akishita, M., Eto, M., Koizumi, H., Hashimoto, R., Ogawa, S., et al. (2012). Src kinase-mediates androgen receptor-dependent non-genomic activation of signaling cascade leading to endothelial nitric oxide synthase. Biochemical and Biophysical Research Communications, 424(3), 538–543. https://doi.org/10.1016/j.bbrc.2012.06.151.CrossRefPubMed

17.

Steinsapir, J., Socci, R., & Reinach, P. (1991). Effects of androgen on intracellular calcium of LNCaP cells. Biochemical and Biophysical Research Communications, 179(1), 90–96. https://doi.org/10.1016/0006-291x(91)91338-d.CrossRefPubMed

18.

Murphy, J. G., & Khalil, R. A. (1999). Decreased [Ca²⁺]_i during inhibition of coronary smooth muscle contraction by 17beta-estradiol, progesterone, and testosterone. The Journal of Pharmacology and Experimental Therapeutics, 291(1), 44–52.PubMed

19.

Ding, A. Q., & Stallone, J. N. (2001). Testosterone-induced relaxation of rat aorta is androgen structure specific and involves K⁺ channel activation. Journal of Applied Physiology, 91(6), 2742–2750. https://doi.org/10.1152/jappl.2001.91.6.2742.CrossRefPubMed

20.

Jones, R. D., English, K. M., Pugh, P. J., Morice, A. H., Jones, T. H., & Channer, K. S. (2002). Pulmonary vasodilatory action of testosterone: Evidence of a calcium antagonistic action. Journal of Cardiovascular Pharmacology, 39(6), 814–823. https://doi.org/10.1097/00005344-200206000-00006.CrossRefPubMed

21.

Cairrao, E., Alvarez, E., Santos-Silva, A. J., & Verde, I. (2008). Potassium channels are involved in testosterone-induced vasorelaxation of human umbilical artery. Naunyn-Schmiedeberg's Archives of Pharmacology, 376(5), 375–383. https://doi.org/10.1007/s00210-007-0213-3.CrossRefPubMed

22.

Teoh, H., Quan, A., Leung, S. W., & Man, R. Y. (2000). Differential effects of 17beta-estradiol and testosterone on the contractile responses of porcine coronary arteries. British Journal of Pharmacology, 129(7), 1301–1308. https://doi.org/10.1038/sj.bjp.0703164.CrossRefPubMedPubMedCentral

23.

Thomas, P., Converse, A., & Berg, H. A. (2018). ZIP9, a novel membrane androgen receptor and zinc transporter protein. General and Comparative Endocrinology, 257, 130–136. https://doi.org/10.1016/j.ygcen.2017.04.016.CrossRefPubMed

24.

Thomas, P. (2019). Membrane androgen receptors unrelated to nuclear steroid receptors. Endocrinology, 160(4), 772–781. https://doi.org/10.1210/en.2018-00987.CrossRefPubMed

25.

Wang, C., Liu, Y., & Cao, J. M. (2014). G protein-coupled receptors: Extranuclear mediators for the non-genomic actions of steroids. International Journal of Molecular Sciences, 15(9), 15412–15425. https://doi.org/10.3390/ijms150915412.CrossRefPubMedPubMedCentral

26.

Hotta, Y., Kataoka, T., & Kimura, K. (2019). Testosterone deficiency and endothelial dysfunction: Nitric oxide, asymmetric dimethylarginine, and endothelial progenitor cells. Sexual Medicine Reviews. https://doi.org/10.1016/j.sxmr.2019.02.005.CrossRef

27.

Higashi, Y. (2017). Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3′,5′-monophosphate pathway. International Journal of Urology, 24(6), 412–424. https://doi.org/10.1111/iju.13336.CrossRefPubMed

28.

Crews, J. K., & Khalil, R. A. (1999). Antagonistic effects of 17 b-estradiol, progesterone, and testosterone on Ca²⁺ entry mechanisms of coronary vasoconstriction. Arteriosclerosis, Thrombosis, and Vascular Biology, 19(4), 1034–1040. https://doi.org/10.1161/01.ATV.19.4.1034.CrossRefPubMed

29.

Deenadayalu, V. P., White, R. E., Stallone, J. N., Gao, X., & Garcia, A. J. (2001). Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. The American Journal of Physiology, 281(4), H1720–H1727. https://doi.org/10.1152/ajpheart.2001.281.4.H1720.CrossRef

30.

Perusquia, M., Hernandez, R., Morales, M. A., Campos, M. G., & Villalon, C. M. (1996). Role of endothelium in the vasodilating effect of progestins and androgens on the rat thoracic aorta. General Pharmacology, 27(1), 181–185. https://doi.org/10.1016/0306-3623(95)00091-7.CrossRefPubMed

31.

Ruamyod, K., Watanapa, W. B., & Shayakul, C. (2017). Testosterone rapidly increases Ca(2+)-activated K(+) currents causing hyperpolarization in human coronary artery endothelial cells. The Journal of Steroid Biochemistry and Molecular Biology, 168, 118–126. https://doi.org/10.1016/j.jsbmb.2017.02.014.CrossRefPubMed

32.

Perusquia, M., Navarrete, E., Gonzalez, L., & Villalon, C. M. (2007). The modulatory role of androgens and progestins in the induction of vasorelaxation in human umbilical artery. Life Sciences, 81(12), 993–1002. https://doi.org/10.1016/j.lfs.2007.07.024.CrossRefPubMed

33.

Yildiz, O., Seyrek, M., Un, I., Gul, H., Candemir, G., & Yildirim, V. (2005). The relationship between risk factors and testosterone-induced relaxations in human internal mammary artery. Journal of Cardiovascular Pharmacology, 45(1), 4–7. https://doi.org/10.1097/00005344-200501000-00002.CrossRefPubMed

34.

Sakamoto, K., & Kurokawa, J. (2019). Involvement of sex hormonal regulation of K(+) channels in electrophysiological and contractile functions of muscle tissues. Journal of Pharmacological Sciences, 139(4), 259–265. https://doi.org/10.1016/j.jphs.2019.02.009.CrossRefPubMed

35.

Martin de Llano, J. J., Fuertes, G., Garcia-Vicent, C., Torro, I., Fayos, J. L., & Lurbe, E. (2007). Procedure to consistently obtain endothelial and smooth muscle cell cultures from umbilical cord vessels. Translational Research, 149(1), 1–9. https://doi.org/10.1016/j.trsl.2006.07.010.CrossRefPubMed

36.

Lorigo, M., Mariana, M., Feiteiro, J., & Cairrao, E. (2018). How is the human umbilical artery regulated? The Journal of Obstetrics and Gynaecology Research. https://doi.org/10.1111/jog.13667.CrossRef

37.

Jackson, W. F. (2005). Potassium channels in the peripheral microcirculation. Microcirculation, 12(1), 113–127. https://doi.org/10.1080/10739680590896072.CrossRefPubMedPubMedCentral

38.

Burg, E. D., Remillard, C. V., & Yuan, J. X. (2008). Potassium channels in the regulation of pulmonary artery smooth muscle cell proliferation and apoptosis: Pharmacotherapeutic implications. British Journal of Pharmacology, 153(Suppl 1), S99–S111. https://doi.org/10.1038/sj.bjp.0707635.CrossRefPubMed

39.

Perusquia, M., & Villalon, C. M. (1999). Possible role of Ca²⁺ channels in the vasodilating effect of 5-beta-dihydrotestosterone in rat aorta. European Journal of Pharmacology, 371(2–3), 169–178. https://doi.org/10.1038/sj.bjp.0707635.CrossRefPubMed

40.

Cairrao, E., Santos-Silva, A. J., & Verde, I. (2010). PKG is involved in testosterone-induced vasorelaxation of human umbilical artery. European Journal of Pharmacology, 640, 94–101. https://doi.org/10.1016/j.ejphar.2010.04.025.CrossRefPubMed

41.

Er, F., Michels, G., Brandt, M. C., Khan, I., Haase, H., Eicks, M., et al. (2007). Impact of testosterone on cardiac L-type calcium channels and Ca²⁺ sparks: Acute actions antagonize chronic effects. Cell Calcium, 41, 467–477. https://doi.org/10.1016/j.ceca.2006.09.003.CrossRefPubMed

42.

Harada, N. (2018). Role of androgens in energy metabolism affecting on body composition, metabolic syndrome, type 2 diabetes, cardiovascular disease, and longevity: Lessons from a meta-analysis and rodent studies. Bioscience, Biotechnology, and Biochemistry, 82(10), 1667–1682. https://doi.org/10.1080/09168451.2018.1490172.CrossRefPubMed

43.

English, K. M., Mandour, O., Steeds, R. P., Diver, M. J., Jones, T. H., & Channer, K. S. (2000). Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. European Heart Journal, 21(11), 890–894. https://doi.org/10.1053/euhj.1999.1873.CrossRefPubMed

44.

Kelly, D. M., & Jones, T. H. (2013). Testosterone: A vascular hormone in health and disease. The Journal of Endocrinology, 217(3), R47–R71. https://doi.org/10.1530/JOE-12-0582.CrossRefPubMed

45.

Chrysant, S. G. (2018). Controversies regarding the cardiovascular effects of testosterone replacement therapy in older men. Drugs Today (Barc), 54(1), 25–34. https://doi.org/10.1358/dot.2018.54.1.2737935.CrossRef

46.

Chrysant, S. G., & Chrysant, G. S. (2018). Cardiovascular benefits and risks of testosterone replacement therapy in older men with low testosterone. Hospital Practice (1995), 46(2), 47–55. https://doi.org/10.1080/21548331.2018.1445405.CrossRef

47.

Gagliano-Juca, T., & Basaria, S. (2019). Testosterone replacement therapy and cardiovascular risk. Nature Reviews. Cardiology, 16(9), 555–574. https://doi.org/10.1038/s41569-019-0211-4.CrossRefPubMed

48.

Pantalone, K. M., George, J., Ji, X., Kattan, M. W., Milinovich, A., Bauman, J. M., et al. (2019). Testosterone replacement therapy and the risk of adverse cardiovascular outcomes and mortality. Basic and Clinical Andrology, 29, 5. https://doi.org/10.1186/s12610-019-0085-7.CrossRefPubMedPubMedCentral

49.

Alberti, K. G., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., et al. (2009). Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 120(16), 1640–1645. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.CrossRef

50.

Armani, A., Berry, A., Cirulli, F., & Caprio, M. (2017). Molecular mechanisms underlying metabolic syndrome: The expanding role of the adipocyte. The FASEB Journal, 31(10), 4240–4255. https://doi.org/10.1096/fj.201601125RRR.CrossRefPubMed

51.

Saklayen, M. G. (2018). The global epidemic of the metabolic syndrome. Current Hypertension Reports, 20(2), 12. https://doi.org/10.1007/s11906-018-0812-z.CrossRefPubMedPubMedCentral

52.

Yaribeygi, H., Farrokhi, F. R., Butler, A. E., & Sahebkar, A. (2019). Insulin resistance: Review of the underlying molecular mechanisms. Journal of Cellular Physiology, 234(6), 8152–8161. https://doi.org/10.1002/jcp.27603.CrossRefPubMed

53.

Corona, G., Monami, M., Rastrelli, G., Aversa, A., Tishova, Y., Saad, F., et al. (2011). Testosterone and metabolic syndrome: A meta-analysis study. The Journal of Sexual Medicine, 8(1), 272–283. https://doi.org/10.1111/j.1743-6109.2010.01991.x.CrossRefPubMed

54.

Corona, G., Rastrelli, G., & Maggi, M. (2013). Diagnosis and treatment of late-onset hypogonadism: Systematic review and meta-analysis of TRT outcomes. Best Practice & Research. Clinical Endocrinology & Metabolism, 27(4), 557–579. https://doi.org/10.1016/j.beem.2013.05.002.CrossRef

55.

Brand, J. S., van der Tweel, I., Grobbee, D. E., Emmelot-Vonk, M. H., & van der Schouw, Y. T. (2011). Testosterone, sex hormone-binding globulin and the metabolic syndrome: A systematic review and meta-analysis of observational studies. International Journal of Epidemiology, 40(1), 189–207. https://doi.org/10.1093/ije/dyq158.CrossRefPubMed

56.

Brand, J. S., Rovers, M. M., Yeap, B. B., Schneider, H. J., Tuomainen, T. P., Haring, R., et al. (2014). Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: An individual participant data meta-analysis of observational studies. PLoS One, 9(7), e100409. https://doi.org/10.1371/journal.pone.0100409.CrossRefPubMedPubMedCentral

57.

Corona, G., Monami, M., Rastrelli, G., Aversa, A., Sforza, A., Lenzi, A., et al. (2011). Type 2 diabetes mellitus and testosterone: A meta-analysis study. International Journal of Andrology, 34(6 Pt 1), 528–540. https://doi.org/10.1111/j.1365-2605.2010.01117.x.CrossRefPubMed

58.

Ding, E. L., Song, Y., Malik, V. S., & Liu, S. (2006). Sex differences of endogenous sex hormones and risk of type 2 diabetes: A systematic review and meta-analysis. JAMA, 295(11), 1288–1299. https://doi.org/10.1001/jama.295.11.1288.CrossRefPubMed

59.

Rao, P. M., Kelly, D. M., & Jones, T. H. (2013). Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nature Reviews. Endocrinology, 9(8), 479–493. https://doi.org/10.1038/nrendo.2013.122.CrossRefPubMed

60.

Wu, F. C., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., et al. (2010). Identification of late-onset hypogonadism in middle-aged and elderly men. The New England Journal of Medicine, 363(2), 123–135. https://doi.org/10.1056/NEJMoa0911101.CrossRefPubMed

61.

Cai, X., Tian, Y., Wu, T., Cao, C. X., Li, H., & Wang, K. J. (2014). Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Asian Journal of Andrology, 16(1), 146–152. https://doi.org/10.4103/1008-682X.122346.CrossRefPubMed

62.

Muka, T., Nano, J., Jaspers, L., Meun, C., Bramer, W. M., Hofman, A., et al. (2017). Associations of steroid sex hormones and sex hormone-binding globulin with the risk of type 2 diabetes in women: A population-based cohort study and meta-analysis. Diabetes, 66(3), 577–586. https://doi.org/10.2337/db16-0473.CrossRefPubMed

63.

Grossmann, M., Hoermann, R., Wittert, G., & Yeap, B. B. (2015). Effects of testosterone treatment on glucose metabolism and symptoms in men with type 2 diabetes and the metabolic syndrome: A systematic review and meta-analysis of randomized controlled clinical trials. Clinical Endocrinology, 83(3), 344–351. https://doi.org/10.1111/cen.12664.CrossRefPubMed

64.

Fruh, S. M. (2017). Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. Journal of the American Association of Nurse Practitioners, 29(S1), S3–S14. https://doi.org/10.1002/2327-6924.12510.CrossRefPubMedPubMedCentral

65.

Benomar, Y., & Taouis, M. (2019). Molecular mechanisms underlying obesity-induced hypothalamic inflammation and insulin resistance: Pivotal role of resistin/TLR4 pathways. Front Endocrinol (Lausanne), 10, 140. https://doi.org/10.3389/fendo.2019.00140.CrossRef

66.

Traish, A. M., Guay, A., Feeley, R., & Saad, F. (2009). The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. Journal of Andrology, 30(1), 10–22. https://doi.org/10.2164/jandrol.108.005215.CrossRefPubMed

67.

Bekaert, M., Van Nieuwenhove, Y., Calders, P., Cuvelier, C. A., Batens, A. H., Kaufman, J. M., et al. (2015). Determinants of testosterone levels in human male obesity. Endocrine, 50(1), 202–211. https://doi.org/10.1007/s12020-015-0563-4.CrossRefPubMedPubMedCentral

68.

Kovac, J. R., Pastuszak, A. W., Lamb, D. J., & Lipshultz, L. I. (2014). Testosterone supplementation therapy in the treatment of patients with metabolic syndrome. Postgraduate Medicine, 126(7), 149–156. https://doi.org/10.3810/pgm.2014.11.2843.CrossRefPubMedPubMedCentral

69.

Bianchi, V. E., & Locatelli, V. (2018). Testosterone a key factor in gender related metabolic syndrome. Obesity Reviews, 19(4), 557–575. https://doi.org/10.1111/obr.12633.CrossRefPubMed

70.

Kelly, D. M., & Jones, T. H. (2015). Testosterone and obesity. Obesity Reviews, 16(7), 581–606. https://doi.org/10.1111/obr.12282.CrossRefPubMed

71.

Chen, R. Y., Wittert, G. A., & Andrews, G. R. (2006). Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes, Obesity & Metabolism, 8(4), 429–435. https://doi.org/10.1111/j.1463-1326.2005.00532.x.CrossRef

72.

Derby, C. A., Zilber, S., Brambilla, D., Morales, K. H., & McKinlay, J. B. (2006). Body mass index, waist circumference and waist to hip ratio and change in sex steroid hormones: The Massachusetts male ageing study. Clinical Endocrinology, 65(1), 125–131. https://doi.org/10.1111/j.1365-2265.2006.02560.x.CrossRefPubMed

73.

Kaukua, J., Pekkarinen, T., Sane, T., & Mustajoki, P. (2003). Sex hormones and sexual function in obese men losing weight. Obesity Research, 11(6), 689–694. https://doi.org/10.1038/oby.2003.98.CrossRefPubMed

74.

Niskanen, L., Laaksonen, D. E., Punnonen, K., Mustajoki, P., Kaukua, J., & Rissanen, A. (2004). Changes in sex hormone-binding globulin and testosterone during weight loss and weight maintenance in abdominally obese men with the metabolic syndrome. Diabetes, Obesity & Metabolism, 6(3), 208–215. https://doi.org/10.1111/j.1462-8902.2004.00335.x.CrossRef

75.

Camacho, E. M., Huhtaniemi, I. T., O'Neill, T. W., Finn, J. D., Pye, S. R., Lee, D. M., et al. (2013). Age-associated changes in hypothalamic-pituitary-testicular function in middle-aged and older men are modified by weight change and lifestyle factors: Longitudinal results from the European male ageing study. European Journal of Endocrinology, 168(3), 445–455. https://doi.org/10.1530/EJE-12-0890.CrossRefPubMed

76.

Cunningham, G. R. (2015). Testosterone and metabolic syndrome. Asian Journal of Andrology, 17(2), 192–196. https://doi.org/10.4103/1008-682X.148068.CrossRefPubMedPubMedCentral

77.

Zhao, J., Zhai, L., Liu, Z., Wu, S., & Xu, L. (2014). Leptin level and oxidative stress contribute to obesity-induced low testosterone in murine testicular tissue. Oxidative Medicine and Cellular Longevity, 2014, 190945. https://doi.org/10.1155/2014/190945.CrossRefPubMedPubMedCentral

78.

Isidori, A. M., Caprio, M., Strollo, F., Moretti, C., Frajese, G., Isidori, A., et al. (1999). Leptin and androgens in male obesity: Evidence for leptin contribution to reduced androgen levels. The Journal of Clinical Endocrinology and Metabolism, 84(10), 3673–3680. https://doi.org/10.1210/jcem.84.10.6082.CrossRefPubMed

79.

Yi, X., Gao, H., Chen, D., Tang, D., Huang, W., Li, T., et al. (2017). Effects of obesity and exercise on testicular leptin signal transduction and testosterone biosynthesis in male mice. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology, 312(4), R501–R510. https://doi.org/10.1152/ajpregu.00405.2016.CrossRefPubMed

80.

Pitteloud, N., Hardin, M., Dwyer, A. A., Valassi, E., Yialamas, M., Elahi, D., et al. (2005). Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men. The Journal of Clinical Endocrinology and Metabolism, 90(5), 2636–2641. https://doi.org/10.1210/jc.2004-2190.CrossRefPubMed

81.

Fink, J., Matsumoto, M., & Tamura, Y. (2018). Potential application of testosterone replacement therapy as treatment for obesity and type 2 diabetes in men. Steroids, 138, 161–166. https://doi.org/10.1016/j.steroids.2018.08.002.CrossRefPubMed

82.

Traish, A. M., & Zitzmann, M. (2015). The complex and multifactorial relationship between testosterone deficiency (TD), obesity and vascular disease. Reviews in Endocrine & Metabolic Disorders, 16(3), 249–268. https://doi.org/10.1007/s11154-015-9323-2.CrossRef

83.

Corona, G., Mannucci, E., Forti, G., & Maggi, M. (2009). Hypogonadism, ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases. International Journal of Andrology, 32(6), 587–598. https://doi.org/10.1111/j.1365-2605.2008.00951.x.CrossRefPubMed

84.

Traish, A. M., Feeley, R. J., & Guay, A. (2009). Mechanisms of obesity and related pathologies: Androgen deficiency and endothelial dysfunction may be the link between obesity and erectile dysfunction. The FEBS Journal, 276(20), 5755–5767. https://doi.org/10.1111/j.1742-4658.2009.07305.x.CrossRefPubMed

85.

Libby, P., Buring, J. E., Badimon, L., Hansson, G. K., Deanfield, J., Bittencourt, M. S., et al. (2019). Atherosclerosis. Nature Reviews. Disease Primers, 5(1), 56. https://doi.org/10.1038/s41572-019-0106-z.CrossRefPubMed

86.

Nezu, T., Hosomi, N., Aoki, S., & Matsumoto, M. (2016). Carotid intima-media thickness for atherosclerosis. Journal of Atherosclerosis and Thrombosis, 23(1), 18–31. https://doi.org/10.5551/jat.31989.CrossRefPubMed

87.

van den Beld, A. W., Bots, M. L., Janssen, J. A., Pols, H. A., Lamberts, S. W., & Grobbee, D. E. (2003). Endogenous hormones and carotid atherosclerosis in elderly men. American Journal of Epidemiology, 157(1), 25–31. https://doi.org/10.1093/aje/kwf160.CrossRefPubMed

88.

Fukui, M., Kitagawa, Y., Nakamura, N., Kadono, M., Mogami, S., Hirata, C., et al. (2003). Association between serum testosterone concentration and carotid atherosclerosis in men with type 2 diabetes. Diabetes Care, 26(6), 1869–1873. https://doi.org/10.2337/diacare.26.6.1869.CrossRefPubMed

89.

Svartberg, J., von Muhlen, D., Mathiesen, E., Joakimsen, O., Bonaa, K. H., & Stensland-Bugge, E. (2006). Low testosterone levels are associated with carotid atherosclerosis in men. Journal of Internal Medicine, 259(6), 576–582. https://doi.org/10.1111/j.1365-2796.2006.01637.x.CrossRefPubMed

90.

De Pergola, G., Pannacciulli, N., Ciccone, M., Tartagni, M., Rizzon, P., & Giorgino, R. (2003). Free testosterone plasma levels are negatively associated with the intima-media thickness of the common carotid artery in overweight and obese glucose-tolerant young adult men. International Journal of Obesity and Related Metabolic Disorders, 27(7), 803–807. https://doi.org/10.1038/sj.ijo.0802292.CrossRefPubMed

91.

Muller, M., van den Beld, A. W., Bots, M. L., Grobbee, D. E., Lamberts, S. W., & van der Schouw, Y. T. (2004). Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation, 109(17), 2074–2079. https://doi.org/10.1161/01.CIR.0000125854.51637.06.CrossRefPubMed

92.

Makinen, J., Jarvisalo, M. J., Pollanen, P., Perheentupa, A., Irjala, K., Koskenvuo, M., et al. (2005). Increased carotid atherosclerosis in andropausal middle-aged men. Journal of the American College of Cardiology, 45(10), 1603–1608. https://doi.org/10.1016/j.jacc.2005.01.052.CrossRefPubMed

93.

Soisson, V., Brailly-Tabard, S., Empana, J. P., Feart, C., Ryan, J., Bertrand, M., et al. (2012). Low plasma testosterone and elevated carotid intima-media thickness: Importance of low-grade inflammation in elderly men. Atherosclerosis, 223(1), 244–249. https://doi.org/10.1016/j.atherosclerosis.2012.05.009.CrossRefPubMed

94.

Farias, J. M., Tinetti, M., Khoury, M., & Umpierrez, G. E. (2014). Low testosterone concentration and atherosclerotic disease markers in male patients with type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism, 99(12), 4698–4703. https://doi.org/10.1210/jc.2014-2585.CrossRefPubMedPubMedCentral

95.

Lee, W. C., Kim, M. T., Ko, K. T., Lee, W. K., Kim, S. Y., Kim, H. Y., et al. (2014). Relationship between serum testosterone and cardiovascular disease risk determined using the Framingham risk score in male patients with sexual dysfunction. The World Journal of Men's Health, 32(3), 139–144. https://doi.org/10.5534/wjmh.2014.32.3.139.CrossRefPubMedPubMedCentral

96.

Wilson, P. W., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998). Prediction of coronary heart disease using risk factor categories. Circulation, 97(18), 1837–1847. https://doi.org/10.1161/01.CIR.97.18.1837.CrossRef

97.

Mahmood, S. S., Levy, D., Vasan, R. S., & Wang, T. J. (2014). The Framingham heart study and the epidemiology of cardiovascular disease: A historical perspective. Lancet, 383(9921), 999–1008. https://doi.org/10.1016/S0140-6736(13)61752-3.CrossRefPubMed

98.

Lee, J. M., Colangelo, L. A., Schwartz, J. E., Yano, Y., Siscovick, D. S., Seeman, T., et al. (2016). Associations of cortisol/testosterone and cortisol/sex hormone-binding globulin ratios with atherosclerosis in middle-age women. Atherosclerosis, 248, 203–209. https://doi.org/10.1016/j.atherosclerosis.2016.03.028.CrossRefPubMedPubMedCentral

99.

Helkin, A., Stein, J. J., Lin, S., Siddiqui, S., Maier, K. G., & Gahtan, V. (2016). Dyslipidemia part 1—Review of lipid metabolism and vascular cell physiology. Vascular and Endovascular Surgery, 50(2), 107–118. https://doi.org/10.1177/1538574416628654.CrossRefPubMed

100.

Stein, R., Ferrari, F., & Scolari, F. (2019). Genetics, dyslipidemia, and cardiovascular disease: New insights. Current Cardiology Reports, 21(8), 68. https://doi.org/10.1007/s11886-019-1161-5.CrossRefPubMed

101.

Shabsigh, R., Katz, M., Yan, G., & Makhsida, N. (2005). Cardiovascular issues in hypogonadism and testosterone therapy. The American Journal of Cardiology, 96(12B), 67M–72M. https://doi.org/10.1016/j.amjcard.2005.10.009.CrossRefPubMed

102.

Haffner, S. M., Mykkanen, L., Valdez, R. A., & Katz, M. S. (1993). Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. The Journal of Clinical Endocrinology and Metabolism, 77(6), 1610–1615. https://doi.org/10.1210/jcem.77.6.8263149.CrossRefPubMed

103.

Agledahl, I., Skjaerpe, P. A., Hansen, J. B., & Svartberg, J. (2008). Low serum testosterone in men is inversely associated with non-fasting serum triglycerides: The Tromso study. Nutrition, Metabolism, and Cardiovascular Diseases, 18(4), 256–262. https://doi.org/10.1016/j.numecd.2007.01.014.CrossRefPubMed

104.

Makinen, J. I., Perheentupa, A., Irjala, K., Pollanen, P., Makinen, J., Huhtaniemi, I., et al. (2008). Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis, 197(2), 688–693. https://doi.org/10.1016/j.atherosclerosis.2007.05.009.CrossRefPubMed

105.

Khaw, K. T., & Barrett-Connor, E. (1991). Endogenous sex hormones, high density lipoprotein cholesterol, and other lipoprotein fractions in men. Arteriosclerosis and Thrombosis, 11(3), 489–494. https://doi.org/10.1161/01.ATV.11.3.489.CrossRefPubMed

106.

Vaidya, D., Dobs, A., Gapstur, S. M., Golden, S. H., Hankinson, A., Liu, K., et al. (2008). The association of endogenous sex hormones with lipoprotein subfraction profile in the multi-ethnic study of atherosclerosis. Metabolism, 57(6), 782–790. https://doi.org/10.1016/j.metabol.2008.01.019.CrossRefPubMedPubMedCentral

107.

Monroe, A. K., & Dobs, A. S. (2013). The effect of androgens on lipids. Current Opinion in Endocrinology, Diabetes, and Obesity, 20(2), 132–139. https://doi.org/10.1097/MED.0b013e32835edb71.CrossRefPubMed

108.

Thompson, P. D., Cullinane, E. M., Sady, S. P., Chenevert, C., Saritelli, A. L., Sady, M. A., et al. (1989). Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA, 261(8), 1165–1168. https://doi.org/10.1001/jama.1989.03420080085036.CrossRefPubMed

109.

Bagatell, C. J., Heiman, J. R., Matsumoto, A. M., Rivier, J. E., & Bremner, W. J. (1994). Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. The Journal of Clinical Endocrinology and Metabolism, 79(2), 561–567. https://doi.org/10.1210/jcem.79.2.8045977.CrossRefPubMed

110.

Kalinchenko, S. Y., Tishova, Y. A., Mskhalaya, G. J., Gooren, L. J., Giltay, E. J., & Saad, F. (2010). Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: The double-blinded placebo-controlled Moscow study. Clinical Endocrinology, 73(5), 602–612. https://doi.org/10.1111/j.1365-2265.2010.03845.x.CrossRefPubMed

111.

Traish, A. M., & Kypreos, K. E. (2011). Testosterone and cardiovascular disease: An old idea with modern clinical implications. Atherosclerosis, 214(2), 244–248. https://doi.org/10.1016/j.atherosclerosis.2010.08.078.CrossRefPubMed

112.

Traish, A. M., Abdou, R., & Kypreos, K. E. (2009). Androgen deficiency and atherosclerosis: The lipid link. Vascular Pharmacology, 51(5–6), 303–313. https://doi.org/10.1016/j.vph.2009.09.003.CrossRefPubMed

113.

Lifton, R. P., Gharavi, A. G., & Geller, D. S. (2001). Molecular mechanisms of human hypertension. Cell, 104(4), 545–556. https://doi.org/10.1016/s0092-8674(01)00241-0.CrossRefPubMed

114.

Zitzmann, M., & Nieschlag, E. (2007). Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. The Journal of Clinical Endocrinology and Metabolism, 92(10), 3844–3853. https://doi.org/10.1210/jc.2007-0620.CrossRefPubMed

115.

Traish, A. M., Miner, M. M., Morgentaler, A., & Zitzmann, M. (2011). Testosterone deficiency. The American Journal of Medicine, 124(7), 578–587. https://doi.org/10.1016/j.amjmed.2010.12.027.CrossRefPubMed

116.

Troisi, R., Potischman, N., Roberts, J. M., Ness, R., Crombleholme, W., Lykins, D., et al. (2003). Maternal serum oestrogen and androgen concentrations in preeclamptic and uncomplicated pregnancies. International Journal of Epidemiology, 32(3), 455–460. https://doi.org/10.1093/ije/dyg094.CrossRefPubMed

117.

Sathishkumar, K., Elkins, R., Yallampalli, U., Balakrishnan, M., & Yallampalli, C. (2011). Fetal programming of adult hypertension in female rat offspring exposed to androgens in utero. Early Human Development, 87(6), 407–414. https://doi.org/10.1016/j.earlhumdev.2011.03.001.CrossRefPubMedPubMedCentral

118.

Chinnathambi, V., Blesson, C. S., Vincent, K. L., Saade, G. R., Hankins, G. D., Yallampalli, C., et al. (2014). Elevated testosterone levels during rat pregnancy cause hypersensitivity to angiotensin II and attenuation of endothelium-dependent vasodilation in uterine arteries. Hypertension, 64(2), 405–414. https://doi.org/10.1161/HYPERTENSIONAHA.114.03283.CrossRefPubMedPubMedCentral

119.

Perez-Sepulveda, A., Monteiro, L. J., Dobierzewska, A., Espana-Perrot, P. P., Venegas-Araneda, P., Guzman-Rojas, A. M., et al. (2015). Placental aromatase is deficient in placental ischemia and preeclampsia. PLoS One, 10(10), e0139682. https://doi.org/10.1371/journal.pone.0139682.CrossRefPubMedPubMedCentral

120.

McClamrock, H. D., & Adashi, E. Y. (1992). Gestational hyperandrogenism. Fertility and Sterility, 57(2), 257–274. https://doi.org/10.1016/S0015-0282(16)54828-6.CrossRefPubMed

121.

Bammann, B. L., Coulam, C. B., & Jiang, N. S. (1980). Total and free testosterone during pregnancy. American Journal of Obstetrics and Gynecology, 137(3), 293–298. https://doi.org/10.1016/0002-9378(80)90912-6.CrossRefPubMed

122.

Honda, H., Unemoto, T., & Kogo, H. (1999). Different mechanisms for testosterone-induced relaxation of aorta between normotensive and spontaneously hypertensive rats. Hypertension, 34(6), 1232–1236. https://doi.org/10.1161/01.HYP.34.6.1232.CrossRefPubMed

123.

Perusquia, M., Herrera, N., Ferrer, M., & Stallone, J. N. (2017). Antihypertensive effects of androgens in conscious, spontaneously hypertensive rats. The Journal of Steroid Biochemistry and Molecular Biology, 167, 106–114. https://doi.org/10.1016/j.jsbmb.2016.11.016.CrossRefPubMed

124.

Isidoro, L., Ferrer, M., & Perusquia, M. (2018). Vasoactive androgens: Vasorelaxing effects and their potential regulation of blood pressure. Endocrine Research, 43(3), 166–175. https://doi.org/10.1080/07435800.2018.1448868.CrossRefPubMed

125.

Perusquia, M., Hanson, A. E., Meza, C. M., Kubli, C., Herrera, N., & Stallone, J. N. (2018). Antihypertensive responses of vasoactive androgens in an in vivo experimental model of preeclampsia. The Journal of Steroid Biochemistry and Molecular Biology, 178, 65–72. https://doi.org/10.1016/j.jsbmb.2017.11.001.CrossRefPubMed

126.

Jones, T. H., & Kelly, D. M. (2018). Randomized controlled trials - mechanistic studies of testosterone and the cardiovascular system. Asian Journal of Andrology, 20(2), 120–130. https://doi.org/10.4103/aja.aja_6_18.CrossRefPubMedPubMedCentral

127.

Tirabassi, G., Gioia, A., Giovannini, L., Boscaro, M., Corona, G., Carpi, A., et al. (2013). Testosterone and cardiovascular risk. Internal and Emergency Medicine, 8(Suppl 1), S65–S69. https://doi.org/10.1007/s11739-013-0914-1.CrossRefPubMed

128.

Phillips, G. B., Castelli, W. P., Abbott, R. D., & McNamara, P. M. (1983). Association of hyperestrogenemia and coronary heart disease in men in the Framingham cohort. The American Journal of Medicine, 74(5), 863–869. https://doi.org/10.1016/0002-9343(83)91078-1.CrossRefPubMed

129.

Zhao, S. P., & Li, X. P. (1998). The association of low plasma testosterone level with coronary artery disease in Chinese men. International Journal of Cardiology, 63(2), 161–164. https://doi.org/10.1016/s0167-5273(97)00295-7.CrossRefPubMed

130.

Chan, Y. X., Knuiman, M. W., Hung, J., Divitini, M. L., Handelsman, D. J., Beilby, J. P., et al. (2015). Testosterone, dihydrotestosterone and estradiol are differentially associated with carotid intima-media thickness and the presence of carotid plaque in men with and without coronary artery disease. Endocrine Journal, 62(9), 777–786. https://doi.org/10.1507/endocrj.EJ15-0196.CrossRefPubMed

131.

Debing, E., Peeters, E., Duquet, W., Poppe, K., Velkeniers, B., & Van Den Brande, P. (2008). Men with atherosclerotic stenosis of the carotid artery have lower testosterone levels compared with controls. International Angiology, 27(2), 135–141.PubMed

132.

Vikan, T., Johnsen, S. H., Schirmer, H., Njolstad, I., & Svartberg, J. (2009). Endogenous testosterone and the prospective association with carotid atherosclerosis in men: The Tromso study. European Journal of Epidemiology, 24(6), 289–295. https://doi.org/10.1007/s10654-009-9322-2.CrossRefPubMed

133.

Yeap, B. B., Alfonso, H., Chubb, S. A., Handelsman, D. J., Hankey, G. J., Golledge, J., et al. (2013). Lower plasma testosterone or dihydrotestosterone, but not estradiol, is associated with symptoms of intermittent claudication in older men. Clinical Endocrinology, 79(5), 725–732. https://doi.org/10.1111/cen.12208.CrossRefPubMed

134.

Rosano, G. M., Sheiban, I., Massaro, R., Pagnotta, P., Marazzi, G., Vitale, C., et al. (2007). Low testosterone levels are associated with coronary artery disease in male patients with angina. International Journal of Impotence Research, 19(2), 176–182. https://doi.org/10.1038/sj.ijir.3901504.CrossRefPubMed

135.

Goodale, T., Sadhu, A., Petak, S., & Robbins, R. (2017). Testosterone and the heart. Methodist DeBakey Cardiovascular Journal, 13(2), 68–72. https://doi.org/10.14797/mdcj-13-2-68.CrossRefPubMedPubMedCentral

136.

Corona, G., Rastrelli, G., Vignozzi, L., Mannucci, E., & Maggi, M. (2011). Testosterone, cardiovascular disease and the metabolic syndrome. Best Practice & Research. Clinical Endocrinology & Metabolism, 25(2), 337–353. https://doi.org/10.1016/j.beem.2010.07.002.CrossRef

137.

Jankowska, E. A., Biel, B., Majda, J., Szklarska, A., Lopuszanska, M., Medras, M., et al. (2006). Anabolic deficiency in men with chronic heart failure: Prevalence and detrimental impact on survival. Circulation, 114(17), 1829–1837. https://doi.org/10.1161/CIRCULATIONAHA.106.649426.CrossRefPubMed

138.

Srinivas-Shankar, U., Roberts, S. A., Connolly, M. J., O'Connell, M. D., Adams, J. E., Oldham, J. A., et al. (2010). Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: A randomized, double-blind, placebo-controlled study. The Journal of Clinical Endocrinology and Metabolism, 95(2), 639–650. https://doi.org/10.1210/jc.2009-1251.CrossRefPubMed

139.

Jeppesen, L. L., Jorgensen, H. S., Nakayama, H., Raaschou, H. O., Olsen, T. S., & Winther, K. (1996). Decreased serum testosterone in men with acute ischemic stroke. Arteriosclerosis, Thrombosis, and Vascular Biology, 16(6), 749–754. https://doi.org/10.1161/01.atv.16.6.749.CrossRefPubMed

140.

Yeap, B. B., Hyde, Z., Almeida, O. P., Norman, P. E., Chubb, S. A., Jamrozik, K., et al. (2009). Lower testosterone levels predict incident stroke and transient ischemic attack in older men. The Journal of Clinical Endocrinology and Metabolism, 94(7), 2353–2359. https://doi.org/10.1210/jc.2008-2416.CrossRefPubMed

141.

Yeap, B. B., Hyde, Z., Norman, P. E., Chubb, S. A., & Golledge, J. (2010). Associations of total testosterone, sex hormone-binding globulin, calculated free testosterone, and luteinizing hormone with prevalence of abdominal aortic aneurysm in older men. The Journal of Clinical Endocrinology and Metabolism, 95(3), 1123–1130. https://doi.org/10.1210/jc.2009-1696.CrossRefPubMed

142.

Magnani, J. W., Moser, C. B., Murabito, J. M., Sullivan, L. M., Wang, N., Ellinor, P. T., et al. (2014). Association of sex hormones, aging, and atrial fibrillation in men: The Framingham heart study. Circulation. Arrhythmia and Electrophysiology, 7(2), 307–312. https://doi.org/10.1161/CIRCEP.113.001322.CrossRefPubMedPubMedCentral

143.

Zeller, T., Schnabel, R. B., Appelbaum, S., Ojeda, F., Berisha, F., Schulte-Steinberg, B., et al. (2018). Low testosterone levels are predictive for incident atrial fibrillation and ischaemic stroke in men, but protective in women - results from the FINRISK study. European Journal of Preventive Cardiology, 25(11), 1133–1139. https://doi.org/10.1177/2047487318778346.CrossRefPubMed

144.

Lai, J., Zhou, D., Xia, S., Shang, Y., Want, L., Zheng, L., et al. (2009). Reduced testosterone levels in males with lone atrial fibrillation. Clinical Cardiology, 32(1), 43–46. https://doi.org/10.1002/clc.20423.CrossRefPubMed

145.

Zhang, Y., Wang, H. M., Wang, Y. Z., Zhang, Y. Y., Jin, X. X., Zhao, Y., et al. (2017). Increment of late sodium currents in the left atrial myocytes and its potential contribution to increased susceptibility of atrial fibrillation in castrated male mice. Heart Rhythm, 14(7), 1073–1080. https://doi.org/10.1016/j.hrthm.2017.01.046.CrossRefPubMed

146.

Rosenberg, M. A., Shores, M. M., Matsumoto, A. M., Bůžková, P., Lange, L. A., Kronmal, R. A., et al. (2018). Serum androgens and risk of atrial fibrillation in older men: The cardiovascular health study. Clinical Cardiology, 41(6), 830–836. https://doi.org/10.1002/clc.22965.CrossRefPubMedPubMedCentral

147.

Berger, D., Folsom, A. R., Schreiner, P. J., Chen, L. Y., Michos, E. D., O'Neal, W. T., et al. (2019). Plasma total testosterone and risk of incident atrial fibrillation: The atherosclerosis risk in communities (ARIC) study. Maturitas, 125, 5–10. https://doi.org/10.1016/j.maturitas.2019.03.015.CrossRefPubMed

148.

O'Neal, W. T., Nazarian, S., Alonso, A., Heckbert, S. R., Vaccarino, V., & Soliman, E. Z. (2017). Sex hormones and the risk of atrial fibrillation: The multi-ethnic study of atherosclerosis (MESA). Endocrine, 58(1), 91–96. https://doi.org/10.1007/s12020-017-1385-3.CrossRefPubMedPubMedCentral

149.

Hackett, G. (2019). Metabolic effects of testosterone therapy in men with type 2 diabetes and metabolic syndrome. Sex Med Rev, 7(3), 476–490. https://doi.org/10.1016/j.sxmr.2018.12.004.CrossRefPubMed

150.

Sizar, O., & Pico, J. (2019). Androgen replacement. In StatPearls. Treasure Island (FL).

151.

Snyder, P. J., Bhasin, S., Cunningham, G. R., Matsumoto, A. M., Stephens-Shields, A. J., Cauley, J. A., et al. (2018). Lessons from the testosterone trials. Endocrine Reviews, 39(3), 369–386. https://doi.org/10.1210/er.2017-00234.CrossRefPubMedPubMedCentral

152.

Budoff, M. J., Ellenberg, S. S., Lewis, C. E., Mohler 3rd, E. R., Wenger, N. K., Bhasin, S., et al. (2017). Testosterone treatment and coronary artery plaque volume in older men with low testosterone. JAMA, 317(7), 708–716. https://doi.org/10.1001/jama.2016.21043.CrossRefPubMedPubMedCentral

153.

Mohler 3rd, E. R., Ellenberg, S. S., Lewis, C. E., Wenger, N. K., Budoff, M. J., Lewis, M. R., et al. (2018). The effect of testosterone on cardiovascular biomarkers in the testosterone trials. The Journal of Clinical Endocrinology and Metabolism, 103(2), 681–688. https://doi.org/10.1210/jc.2017-02243.CrossRefPubMed

154.

Keya, S. L., Khanam, N. N., Chowdhury, A. A., Ripon, R., Tasnim, T., & Sharmin, A. (2019). Relationship between free testosterone and preeclampsia. Mymensingh Medical Journal, 28, 574–581.PubMed

155.

Kloner, R. A., Carson 3rd, C., Dobs, A., Kopecky, S., & Mohler 3rd, E. R. (2016). Testosterone and cardiovascular disease. Journal of the American College of Cardiology, 67(5), 545–557. https://doi.org/10.1016/j.jacc.2015.12.005.CrossRef

156.

Baillargeon, J., Urban, R. J., Kuo, Y. F., Ottenbacher, K. J., Raji, M. A., Du, F., et al. (2014). Risk of myocardial infarction in older men receiving testosterone therapy. The Annals of Pharmacotherapy, 48(9), 1138–1144. https://doi.org/10.1177/1060028014539918.CrossRefPubMedPubMedCentral

157.

Dobrzycki, S., Serwatka, W., Nadlewski, S., Korecki, J., Jackowski, R., Paruk, J., et al. (2003). An assessment of correlations between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. The Journal of Medical Investigation, 50, 162–169.PubMed

158.

Soisson, V., Brailly-Tabard, S., Helmer, C., Rouaud, O., Ancelin, M. L., Zerhouni, C., et al. (2013). A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: The French 3C cohort study. Maturitas, 75(3), 282–288. https://doi.org/10.1016/j.maturitas.2013.04.012.CrossRefPubMed

159.

Muraleedharan, V., Marsh, H., Kapoor, D., Channer, K. S., & Jones, T. H. (2013). Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology, 169(6), 725–733. https://doi.org/10.1530/EJE-13-0321.CrossRefPubMed

160.

Jankowska, E. A., Filippatos, G., Ponikowska, B., Borodulin-Nadzieja, L., Anker, S. D., Banasiak, W., et al. (2009). Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure. Journal of Cardiac Failure, 15(5), 442–450. https://doi.org/10.1016/j.cardfail.2008.12.011.CrossRefPubMed

161.

Pugh, P. (2003). Acute haemodynamic effects of testosterone in men with chronic heart failure. European Heart Journal, 24(10), 909–915. https://doi.org/10.1016/s0195-668x(03)00083-6.CrossRefPubMed

162.

Malkin, C. J., Pugh, P. J., Jones, R. D., Kapoor, D., Channer, K. S., & Jones, T. H. (2004). The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. The Journal of Clinical Endocrinology and Metabolism, 89(7), 3313–3318. https://doi.org/10.1210/jc.2003-031069.CrossRefPubMed

163.

Deenadayalu, V., Puttabyatappa, Y., Liu, A. T., Stallone, J. N., & White, R. E. (2012). Testosterone-induced relaxation of coronary arteries: Activation of BKCa channels via the cGMP-dependent protein kinase. American Journal of Physiology. Heart and Circulatory Physiology, 302(1), H115–H123. https://doi.org/10.1152/ajpheart.00046.2011.CrossRefPubMed

164.

Jones, R. D., Pugh, P. J., Jones, T. H., & Channer, K. S. (2003). The vasodilatory action of testosterone: A potassium-channel opening or a calcium antagonistic action? British Journal of Pharmacology, 138(5), 733–744.CrossRef

165.

Oskui, P. M., French, W. J., Herring, M. J., Mayeda, G. S., Burstein, S., & Kloner, R. A. (2013). Testosterone and the cardiovascular system: A comprehensive review of the clinical literature. Journal of the American Heart Association, 2(6), e000272. https://doi.org/10.1161/JAHA.113.000272.CrossRefPubMedPubMedCentral

166.

Vigen, R., O'Donnell, C. I., Baron, A. E., Grunwald, G. K., Maddox, T. M., Bradley, S. M., et al. (2013). Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA, 310(17), 1829–1836. https://doi.org/10.1001/jama.2013.280386.CrossRefPubMed

167.

Finkle, W. D., Greenland, S., Ridgeway, G. K., Adams, J. L., Frasco, M. A., Cook, M. B., et al. (2014). Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One, 9(1), e85805. https://doi.org/10.1371/journal.pone.0085805.CrossRefPubMedPubMedCentral

168.

Webb, C. M., & Collins, P. (2017). Role of testosterone in the treatment of cardiovascular disease. European Cardiology, 12(2), 83–87. https://doi.org/10.15420/ecr.2017:21:1.CrossRef

169.

Morgentaler, A., & Kacker, R. (2014). Andrology: Testosterone and cardiovascular risk—Deciphering the statistics. Nature Reviews. Urology, 11(3), 131–132. https://doi.org/10.1038/nrurol.2014.24.CrossRefPubMed

170.

Sharma, R., Oni, O. A., Gupta, K., Chen, G., Sharma, M., Dawn, B., et al. (2015). Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. European Heart Journal, 36(40), 2706–2715. https://doi.org/10.1093/eurheartj/ehv346.CrossRefPubMed

171.

Cheetham, T. C., An, J., Jacobsen, S. J., Niu, F., Sidney, S., Quesenberry, C. P., et al. (2017). Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Internal Medicine, 177(4), 491–499. https://doi.org/10.1001/jamainternmed.2016.9546.CrossRefPubMed

172.

Chistiakov, D. A., Myasoedova, V. A., Melnichenko, A. A., Grechko, A. V., & Orekhov, A. N. (2018). Role of androgens in cardiovascular pathology. Vascular Health and Risk Management, 14, 283–290. https://doi.org/10.2147/VHRM.S173259.CrossRefPubMedPubMedCentral

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Vascular Pathways of Testosterone: Clinical Implications

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2020

Gender Differences in Arrhythmias: Focused on Atrial Fibrillation

Sex-Specific Aspects in the Pathophysiology and Imaging of Coronary Macro- and Microvascular Disease

Sex and Gender Differences in Ischemic Heart Disease: Endocrine Vascular Disease Approach (EVA) Study Design

Correction to: Sex and Gender Differences in Ischemic Heart Disease: Endocrine Vascular Disease Approach (EVA) Study Design